Morgan Lewis on Life Sciences
September/October 2004

In this Issue:

• OIG Crosshairs Shift to Medical Device Manufacturers:
  Aggressive federal and state scrutiny of and enforcement against pharmaceutical companies and providers for anti-kickback violations and healthcare fraud and abuse have been well publicized. With the closing of many of these investigations, the government is now shifting its focus to another healthcare sector — manufacturers of medical supplies and devices — and is pursuing the device industry with the same zeal witnessed in the provider and pharmaceutical industries.
• FTC Consent Settlements Continue Close Scrutiny of Pharmaceutical Industry:
  wo recent FTC consent agreements — the first involving the pioneer manufacturer of a product designed to combat breakthrough cancer pain (BTCP) and the other concerning a maker of OTC children’s liquid ibuprofen — demonstrate that the FTC continues to apply close scrutiny to pharmaceutical industry participants and to activities and practices within the industry. The FTC and the DOJ Antitrust Division can be expected to continue to closely monitor and take enforcement actions against life sciences industry companies, as outlined in their recent, voluminous joint report on Improving Health Care: A Dose of Competition.
• Sponsored Events
• Speeches & Articles

For the full story, please view the PDF.